A single-center analysis of patients with extranodal marginal zone lymphoma of the breast

Sunil Girish Iyer, Russ Kuker, Jorge A. Florindez, Eduardo Saul, Asaad Trabolsi, Gregor Rodriguez, Jennifer R. Chapman, Izidore S. Lossos, Juan Pablo Alderuccio

Research output: Contribution to journalArticlepeer-review


Breast extranodal marginal zone lymphoma (EMZL) is a rare malignancy. We performed the largest published to date single-center retrospective analysis of 13 patients with breast EMZL focusing on clinical characteristics and treatment-related outcomes. The rarity of this disease at our center was concordant with the prevalence reported in the literature, with breast EMZL comprising 2% of 654 MZL cases. Most patients presented with stage I-II disease however four (30.8%) patients had stage IV disease mostly due to occult bone marrow (BM) involvement. Interestingly, EMZL was frequently non-FDG avid (66.7%) on staging PET/CT. With a median follow-up of 3.1 years (range 5 months to 10.2 years), the 3-year progression free survival was 68.7% (95%CI 30.2%–88.9%) and overall survival 80.2% (95%CI 40.3%-94.8%). No patient experienced higher-grade transformation. Herein we show that localized breast EMZL can be effectively treated with radiation therapy providing long term disease control.

Original languageEnglish (US)
JournalLeukemia and Lymphoma
StateAccepted/In press - 2021


  • Extranodal marginal zone lymphoma; breast lymphoma; treatment-related outcomes

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research


Dive into the research topics of 'A single-center analysis of patients with extranodal marginal zone lymphoma of the breast'. Together they form a unique fingerprint.

Cite this